NCT03041363 is a Phase 1 clinical trial of Triheptanoin in Epilepsy, sponsored by Juan Pascual.

Who is sponsoring NCT03041363?

NCT03041363 is sponsored by Juan Pascual.

What drugs are being tested in NCT03041363?

Interventions in NCT03041363: Triheptanoin.

What condition does NCT03041363 study?

NCT03041363 studies Epilepsy, GLUT1DS1, Glut1 Deficiency Syndrome 1, Autosomal Recessive, Glucose Metabolism Disorders, Glucose Transport Defect, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter Protein Type 1 Deficiency Syndrome.

Is NCT03041363 still recruiting?

NCT03041363 is currently completed. Last updated 22 December 2022.

Last reviewed 2022-12-22 · How we verify

NCT03041363

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment Development of Triheptanoin (G1D)

Completed Phase 1 Last updated 22 December 2022

What this trial tests

Phase 1 trial testing Triheptanoin in Epilepsy in 12 participants. Completed in 22 December 2017.

Timeline

29 March 2017

Primary endpoint
22 December 2017

22 December 2017

Quick facts

Lead sponsor	Juan Pascual
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	29 March 2017
Primary completion	22 December 2017
Estimated completion	22 December 2017
Sites	1 location across United States

Drugs / interventions tested

Triheptanoin — full drug profile →

Conditions studied

Epilepsy — all drugs for Epilepsy →
GLUT1DS1 — all drugs for GLUT1DS1 →
Glut1 Deficiency Syndrome 1, Autosomal Recessive — all drugs for Glut1 Deficiency Syndrome 1, Autosomal Recessive →
Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →

Sponsor

Juan Pascual

Who can join

Adults 2 to 35, any sex, with Epilepsy or GLUT1DS1. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the maximum tolerated dose (MTD), as a percentage of calories consumed, of triheptanoin (C7 oil; C7) in a pediatric and adult patient population genetically diagnosed with glucose transporter type 1 deficiency disorder (G1D).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Glut1 Deficiency Syndrome (Glut1DS): State of the art in 2020 and recommendations of the international Glut1DS study group.
Klepper J, Akman C, Armeno M, Auvin S, et al · · 2020 · cited 186× · PMID 32913944 · DOI 10.1002/epi4.12414
Development and validation of a LC-MS/MS method for quantitation of 3-hydroxypentanoic acid and 3-oxopentanoic acid in human plasma and its application to a clinical study of glucose transporter type I deficiency (G1D) syndrome.
Kallem RR, Primeaux S, Avila A, Pascual JM, et al · · 2021 · cited 3× · PMID 34482182 · DOI 10.1016/j.jpba.2021.114335
Maximum dose, safety, tolerability and ketonemia after triheptanoin in glucose transporter type 1 deficiency (G1D).
Málaga I, Avila A, Primeaux S, Kallem RR, et al · · 2023 · cited 1× · PMID 36859467 · DOI 10.1038/s41598-023-30578-z

Verify or expand the search:

Other trials of Triheptanoin

Trials testing the same drug.

NCT06340685 — Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency · Phase 1 · recruiting
NCT04513002 — Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis · Phase 2 · completed
NCT03665636 — Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I · EARLY_PHASE1 · completed
NCT03642860 — The Effect of Triheptanoin on Fatty Acid Oxidation and Exercise Tolerance in Patients With Glycogenoses · Phase 2 · completed
NCT03506425 — A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) · Phase 1, PHASE2 · completed

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting

Other Juan Pascual trials

Trials by the same sponsor.

NCT02018302 — Post Study Continuation of C7 for G1D · no longer available

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03041363 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Juan Pascual
Last refreshed: 22 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03041363.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing